Actuate Therapeutics (ACTU ... The primary objectives of this Phase 2 open-label, non-comparator study are to determine the safety, tolerability, and progression-free survival of the combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback